Meyre, Pascal B.
Aeschbacher, Stefanie
Blum, Steffen
Voellmin, Gian
Kastner, Peter M.
Hennings, Elisa
Kaufmann, Beat A.
Kühne, Michael
Osswald, Stefan
Conen, David
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (3232B0_141603, PP00P3_159322)
Mach Gaensslen Foundation
Swiss National Science Foundation (PP00P3_133681)
Article History
Received: 5 November 2021
Accepted: 13 January 2022
First Online: 31 January 2022
Competing interests
: Dr. Kühne reports personal fees from Bayer, personal fees from Böhringer Ingelheim, personal fees from Pfizer BMS, personal fees from Daiichi Sankyo, personal fees from Medtronic, personal fees from Biotronik, personal fees from Boston Scientific, personal fees from Johnson&Johnson, grants from Bayer, Grants from Pfizer, Grants from Boston Scientific, Grants from BMS, Grants from Biotronik. Grants from the Swiss National Science Foundation (Grant Numbers 33CS30_148474, 33CS30_177520, 32473B_176178), the Swiss Heart Foundation, the Foundation for Cardiovascular Research Basel and the University of Basel. Dr. Conen has received consultant/speaker fees from Roche Diagnostics; and BMS/Pfizer, both outside of the current work, Canada outside of the current work. The remaining authors have nothing to disclose.